20/20 Biolabs, Inc. Common Stock (AIDX)vsStryker Corporation (SYK)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.20
+0.25%
HEALTHCARE · Cap: $2.62M
SYK
Stryker Corporation
$309.64
+0.35%
HEALTHCARE · Cap: $118.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 1288989% more annual revenue ($26.30B vs $2.04M). SYK leads profitability with a 13.8% profit margin vs -285.0%. SYK earns a higher WallStSmart Score of 53/100 (C-).
AIDX
Hold36
out of 100
Grade: F
SYK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-31.3%
Fair Value
$235.85
Current Price
$309.64
$73.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 24.0%
Generating 1.2B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -354.6% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AIDX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.77 — expect wider price swings.
AIDX is growing revenue faster at 36.5% — sustainability is the question.
SYK generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (53/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?